Suven Life Sciences secures US patent

The US Patent and Trademark Office ( PTO) has granted Suven Life Sciences a product patent. The granted claims of the patent include the class of selective serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents.

According to the invention patent disclosure, the compounds are useful in the treatment of neuro-degenarative disorders like Alzheimer's disease, Parkinson's disease, schizophrenia and Huntington's disease. This is Suven's second product patent granted in the US.

"We are very pleased by the issuance of this patent to Suven by the US Patent office for our drug candidates that are being developed for central nervous system (CNS) disorders which targets a $18 billion potential market opportunity," Venkat Jasti, CEO of Suven, said today.

Suven has filed 29 product patent applications through the Patent Cooperation Treaty (PCT), covering more than 145 countries. Of these, 5 product patents are granted in various countries.

Several other patent applications from Suven Discovery Research are in the pipeline that have completed the administrative and technical diligence from the patent offices from major countries and would be granted shortly.